Hereditary Testing Market Is Continuing Growth During Forecast Period 2022 - 2030.
The global hereditary testing market size is expected to reach USD 13.6 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 9.2% from 2022 to 2030. Key factors driving the market are the declining cost of sequencing and the availability of genetic tests at a lower price. Furthermore, the availability of niche and fragmented point solutions across the genomics value chain, namely sequencing, analytics, interpretation, aggregation, and marketplace, is anticipated to propel the market growth over the forecast period.
The advent of direct-to-consumer genetics is anticipated to play a major role in the genetic testing market by enabling individuals to carry out self-testing. This expands the role of genetic counselors, which further aids in understanding the importance of genetic tests and helps in the selection of appropriate tests. A growing number of registered genetic counselors is anticipated to boost the adoption of hereditary genetic tests in the coming years.
Another important market trend is the growing field of reproductive genetic health. For instance, Natera has seen a consistent increase in test numbers in hereditary illnesses genetic analysis for women's health. This indicates a rise in public acceptance of hereditary testing, which is fueling the market expansion. A rise in the trade of newborn screening equipment has corresponded with a rise in the trade of DNA experiment equipment. Progressing the sharpness of newborn screening all over the world is also assisting in earnings increase. A multigene board trial was formed for introducing genetic melanoma into the clinical application, which has been prompted by changes in genetic experimentation standards. The growing generative hereditary health scope is one of the most important key factors driving the market.
Hereditary Testing Market Segmentation
Grand View Research has segmented the global hereditary testing market based on disease type and region:
Based on the Disease Type Insights, the market is segmented into Hereditary Cancer Testing and Hereditary Non-cancer Testing.
- The hereditary non-cancer testing segment dominated the market with a revenue share of over 80.0% in 2021 and is expected to expand at a significant CAGR over the forecast period. Product and service offerings with regard to various hereditary cancer testing continue to expand. The entry of major players, such as Quest, in this segment in the recent past, has significantly driven the market.
- One of the strategies is offering hereditary tests at a price lower than that offered by competitors. For instance, Color Genomics began selling its product for USD 259, whereas similar products offered by Myriad cost around USD 4,000. The increasing affordability of the tests is one of the key drivers of this segment. Furthermore, BRCA1 carriers have an 80% risk of developing breast cancer, which has also accelerated the developments in the hereditary cancer testing market.
- Lung cancer is one of the major cancer forms that has relatively few products. This is because most cases of lung cancer are not related to inherited genetic mutations. Similarly, for cervical cancer, most of the cases are caused by Human Papilloma Virus (HPV) and not genetic mutations. The lack of effective evidence on the heritability of cervical cancer is driving the research activities in this market.
- Prenatal testing, irrespective of the associated risks, is increasingly gaining popularity. The cell-free DNA (cfDNA)-based NIPT testing is considered medically necessary by Anthem Blue Cross and Blue Shield of California. Previously, these players promoted cfDNA-based NIPT testing for trisomy’s 21, 18, and 13 only in high-risk pregnancies as determined by maternal age and other factors.
Hereditary Testing Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Key Companies Profile & Market Share Insights
Understanding the role of genetic mutation in disease occurrence has significantly accelerated the R&D in this market. Various retrospective studies are being carried out to understand the role of inherited mutations in disease pathology, which has led to key diagnostic developers, such as Quest Diagnostics, entering the market. Continuous authorizations and approvals of genetic tests by the government are expected to propel the organic revenue growth of operating companies. Furthermore, the expanding product portfolio is indicative of growing competition in the market. Each company is making focused efforts to offer products with a competitive advantage.
Some prominent players in the Global Hereditary Testing market include:
- Myriad Genetics, Inc.
- Invitae Corporation
- Illumina, Inc.
- Natera, Inc.
- Laboratory Corporation of America Holdings
- F. Hoffmann-La Roche Ltd.
- Quest Diagnostics Incorporated
- CooperSurgical, Inc.
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- Twist Bioscience
- Sophia Genetics
- Fulgent Genetics, Inc.
- MedGenome
- CENTOGENE N.V.
Order a free sample PDF of the in Hereditary Testing Market Intelligence Study, published by Grand View Research.
Comments
Post a Comment